Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01577251
Other study ID # UPCC 11908
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date June 2008
Est. completion date December 2030

Study information

Verified date June 2023
Source Abramson Cancer Center at Penn Medicine
Contact Jay Dorsey, MD, PhD
Phone 855-216-0098
Email PennCancerTrials@emergingmed.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The goal of this study is two-fold: to establish a tissue banking respository (defined as blood, urine, soft tissue, tumor specimen, and normal tissue from areas surrounding tumor specimens), and to prospectively assess health related quality of life (QOL) over time in patients with a pathologically confirmed diagnosis of neoplasia receiving radiotherapy or photodynamic therapy (PDT)


Recruitment information / eligibility

Status Recruiting
Enrollment 8000
Est. completion date December 2030
Est. primary completion date December 2030
Accepts healthy volunteers No
Gender All
Age group 18 Years to 89 Years
Eligibility Inclusion Criteria: - Anyone age 18 and above with a cancer diagnosis - Able to sign consent

Study Design


Related Conditions & MeSH terms

  • Neoplasms
  • Patients With Pathologically Confirmed Neoplasia That Have Been
  • Selected for Definitive Photodynamic Therapy, Proton, or Photon Radiation Therapy

Locations

Country Name City State
United States Abramson Cancer Center of the University of Pennsylvania Philadelphia Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Abramson Cancer Center at Penn Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Health Assessments 10 years